Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties

Jialin Cai a,1, Bin Li b,c,1, Yan Zhu d,1, Xuqian Fang a, Mingyu Zhu e, Mingjie Wang e, Shupeng Liu d, Xiaoqing Jiang b,c,1, Jianming Zheng a,c,1, XinXin Zhang a,c,1,⁎⁎⁎ Peizhan Chen a,⁎⁎

a Translational Medicine Research Center, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai 201821, PR China
b Biliary Tract Surgery Department I, Eastern Hepatobiliary Surgery Hospital, Secondary Military Medical University, Shanghai 200433, PR China
c Diagnosis and Treatment Center of Malignant Biliary Tract Diseases, Secondary Military Medical University, Shanghai 200433, PR China
d Department of Pathology, Changzhai Hospital, Secondary Military Medical University, Shanghai 200433, PR China
e Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, PR China

⁎ Corresponding to: Peizhan Chen, Translational Medicine Research Center, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Xi Wang Road 999, Shanghai 201821, PR China.
⁎⁎⁎ Corresponding to: XinXin Zhang, Department of Infectious Diseases, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, PR China.
⁎⁎⁎⁎⁎⁎ Corresponding to: Jianming Zheng, Department of Pathology, Changzhai Hospital, Secondary Military Medical University, Shanghai 200433, PR China.
E-mail addresses: jzhu@163.com (J. Zheng), xin-xin-zhang@163.com (X. Zhang), pchen@nwme.com (P. Chen).

1 These authors contributed equally to the study.

A R T I C L E   I N F O

Article history:
Received 5 January 2017
Received in revised form 7 April 2017
Accepted 7 April 2017
Available online 12 April 2017

Keywords:
Hepatocellular carcinoma
Overall survival
Biomarker
Network
Gene signature

A B S T R A C T

Many molecular classification and prognostic gene signatures for hepatocellular carcinoma (HCC) patients have been established based on genome-wide gene expression profiling; however, their generalizability is unclear. Herein, we systematically assessed the prognostic effects of these gene signatures and identified valuable prognostic biomarkers by integrating these gene signatures. With two independent HCC datasets (GSE14520, N = 242 and GSE54236, N = 78), 30 published gene signatures were evaluated, and 11 were significantly associated with the overall survival (OS) of postoperative HCC patients in both datasets. The random survival forest models suggested that the gene signatures were superior to clinical characteristics for predicting the prognosis of the patients. Based on the 11 gene signatures, a functional protein-protein interaction (PPI) network with 1406 nodes and 10,135 edges was established. With tissue microarrays of HCC patients (N = 60), we determined the prognostic values of the core genes in the network and found that RAD21, CDK1, and HDAC2 expression levels were negatively associated with OS for HCC patients. The multivariate Cox regression analyses suggested that CDK1 was an independent prognostic factor, which was validated in an independent case cohort (N = 78). In cellular models, inhibition of CDK1 by siRNA or a specific inhibitor, RO-3306, reduced cellular proliferation and viability for HCC cells. These results suggest that the prognostic predictive capacities of these gene signatures are reproducible and that CDK1 is a potential prognostic biomarker or therapeutic target for HCC patients.

© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

For men and women worldwide, liver cancer ranks as the second and sixth leading cause of cancer deaths, respectively (Torre et al., 2015). In 2012, there were an estimated 782,500 new cases of liver cancer and 745,500 deaths worldwide, and the incidence of the disease is rising (Torre et al., 2015). In 2012, there were an estimated 782,500 new cases of liver cancer and 745,500 deaths worldwide, and the incidence of the disease is rising (Torre et al., 2015). Hepatocellular carcinoma (HCC) account for 90% of primary liver cancer cases, and epidemiological studies have revealed that chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, exposure to aflatoxin, alcohol consumption, cigarette smoking, diabetes, and susceptibility genetic factors are major risk factors for HCC (Donato et al., 2002; El-Serag, 2012; Yang et al., 2011). The prognosis for HCC patients is poor: the 5-year survival rate for localized HCC patients is 30.5%, and this rate drops below 5% for those with distant metastases according to the Surveillance, Epidemiology, and End Results (SEER) database (El-Fattah et al., 2017; Oweira et al., 2017). For patients at early disease stages, liver resection is the most effective treatment methods; however, fewer than 30% of HCC patients are eligible for this treatment, and approximately 70% of them will relapse within 5 years of treatment (Intaraprasong et al., 2016). Thus, it is necessary to identify those prognostic factors and systematically evaluate patient characteristics to guide the postoperative treatments and surveillance, which may improve the prognosis of HCC patients.

Similar to other solid tumors, the characteristics such as tumor size, tumor differentiation, tumor node numbers, vascular invasion, and metastasis status are important prognosis factors for HCC patients (Noh et al., 2016). These characteristics constitute the tumor-node-metastasis (TNM) classification system for HCC patients (Sobin, 2003). In addition...
to these tumor characteristics, biomarkers for preserved liver function and the liver damage status of the HCC patients, such as the Child-Pugh stage; the α-fetoprotein (AFP), bilirubin, and albumin levels; and ECOG status are also associated with the prognosis of HCC patients. These additionally markers have led to the establishment of various conventional staging systems, including the Japanese Integrated Staging (JIS) system (Kudo et al., 2003), the Barcelona Clinic Liver Cancer (BCLC) classification system (Llovet et al., 1999), the Cancer of the Liver Italian Program (CLIP) scoring system (No-author-listed, 1998) and the Chinese University Prognostic Index (CUPi) scoring system (Leung et al., 2002). These systems are widely used to guide the treatment methods and/or predict the outcomes of HCC patients. However, the clinical performance of these systems depends on the patient characteristics, the treatments performed, and the disease etiology of the patients (Marrero et al., 2010; Subramaniam et al., 2013). Moreover, although these staging and scoring systems can stratify the HCC patients into appropriate risk categories, a great deal of divergence remains within each risk category due to the molecular heterogeneity of tumor cells and the tumor microenvironment (Fridman et al., 2012). An in-depth characterization and understanding of the molecular basis of the tumor and its corresponding microenvironment are critical for improving the diagnosis, identifying prognostic and predictive biomarkers, and developing effective therapeutic strategies (Koren and Bentires-Alj, 2015).

Genome-wide expression profiling methods provide detailed information regarding the diversity of diseases and are valuable for the disease diagnosis, therapeutic response prediction and prognosis evaluation. Currently, many studies have assessed the prognostic effects of array-based gene expression signatures obtained from HCC tumors (Andersen et al., 2010; Boyault et al., 2007; Cairo et al., 2008; Chew et al., 2012; Chiang et al., 2008; Couloaum et al., 2008; Hoshida et al., 2009; Iizuka et al., 2003; Kaposi-Novak et al., 2006; Kim et al., 2012; Ko et al., 2014; Kurokawa et al., 2004; Lee et al., 2004; Lim et al., 2013; Minguet et al., 2011; Roessler et al., 2010; Roessler et al., 2012; Sakai et al., 2008; Villanueva et al., 2008; Wang et al., 2007; Woo et al., 2010; Woo et al., 2008; Yamashita et al., 2008; Ye et al., 2003; Yoshioka et al., 2009) or from adjacent, non-tumor tissues (Budhu et al., 2006; Hoshida et al., 2008; Okamoto et al., 2006). These investigations have identified gene signatures that predict recurrence and/or mortality for HCC patients; however, none has entered clinical use, perhaps due to their low reproducibility and lack of standardized determination methods. Interestingly, overlapping genes between these gene signatures are rare, and this rarity may be related to the disease stage of the patients, the main hypothesis of the study, the platform applied, and/or the data mining methods that were utilized. However, these gene signatures with little overlap might be functionally linked with each other and form a systematic molecular regulation network that is robust for patient stratification. Herein, we systematically evaluated the generalization of the prognostic gene signatures in independent HCC case cohorts and established a functional protein–protein interaction (PPI) network for gene signatures that have reproducible prognostic values. Through the PPI network topological analysis, we identified those critical molecules in the network and determined their values as biomarkers for prognosis assessment or as therapeutic targets for HCC patients.

2. Methods and Materials

2.1. Identification of Candidate HCC Prognostic Gene Signatures

The PubMed database, published up to April 30, 2016, was searched to identify gene signatures that have prognostic effects for HCC patients. The terms (“liver cancer” or “hepatocellular carcinoma”) AND (“prognosis” or “overall survival” or “outcome” or “mortality”) AND (“gene expression” or “gene signature” or “expression profiling”) were used. A total of 1713 original publications were identified in our initial database search. Through checking the titles and abstracts of studies, we excluded those studies that were only performed in the cellular or animal models but not in the human populations. Comments, reviews, abstracts or short communications without sufficient information were also excluded. Thus, 89 publications were selected and further checked in full length to identify gene signatures that might be associated with the overall survival (OS) of HCC patients. Excluded were gene signatures derived from cell lines, specific biological signaling, microRNA expression, long non-coding RNA expression, and methods based on real-time PCR (RT-PCR). Gene signatures derived from tumor microenvironment samples were also excluded because we specifically focused on gene expression information derived from the tumor tissues here. A total of 30 gene signatures from 25 studies were identified, and their prognostic performance in HCC patients was determined [15-39] (Table 1).

2.2. Identification of Gene Expression Datasets and Data Processing

The NCBI GEO (http://www.ncbi.nlm.nih.gov/geo/) and ArrayExpress (http://www.ebi.ac.uk/arrayexpress/) databases were searched to identify datasets that had determined the prognostic effects of genome-wide gene expression levels. Eligible datasets should have determined the gene expression level in the HCC tumor tissues at the genome-wide level and provided the OS time and the corresponding status (alive or dead) at the last follow-up. OS was defined as the time range from the day of surgery to death or the last follow-up. Datasets that only provided gene expression levels in adjacent normal tissues or did not provide prognostic information for the patients were excluded. Initially, 97 datasets were identified for HCC, and 78 were excluded because they were based on formalin-fixed, paraffin-embedded (FFPE) tissues, cell lines, non-tumor tissues, or animal models. Additionally, 17 datasets that did not provide prognostic information for the HCC patients were also excluded after we carefully checked the original reports or emailed the authors. GEO: GSE14520 (Roessler et al., 2010; Roessler et al., 2012) and GEO: GSE4236 (Villa et al., 2016) datasets fully met the inclusion criteria and were defined as the validation case-cohorts for the gene signatures in our current study.

GSE14520 dataset consisted of tissues from 242 patients with primary HCCs, who underwent radical resections between 2002 and 2003 at the Liver Cancer Institute and Zhongshan Hospital (Fudan University, Shanghai, China). From this cohort, 220 samples were analyzed with the Affymetrix HT Human Genome U133A Array (GPL3921 platform with 22,277 probes), and 22 samples were analyzed with the Affymetrix Human Genome U133A 2.0 Array (GPL571 platform with 22,277 probes). The raw expression data were processed and normalized by the Robust Multi-Array Average (RMA) method and global median centering. The array series was combined according to the probe IDs, and batch effects were adjusted with empirical Bayes methods in the Combat package of R software. For genes with more than one probe set, the mean level was calculated to obtain the individual gene expression level. Detailed clinical information was provided by Roessler et al. (Roessler et al., 2010).

GSE4236 dataset consisted of tissues from 78 primary HCC patients who received surgery at the Modena Gastroenterology Unit, Italy (Villa et al., 2016). The gene expression levels of the HCC tissues were determined with the Agilent Whole Human Genome Microarray 4×44K array with 41,000 probes. The expression levels were processed with Agilent Feature Extraction Software, and the quantile normalized log2 signal intensity data were downloaded from the GEO datasets. The mean level for probes from the same gene was calculated to determine the gene expression level. Detailed information for the patients was provided by Villa et al. (Villa et al., 2016).

2.3. Recruitment of HCC Patients

A retrospective study was performed for HCC patients (N = 60) who received surgery treatment with curative intent from July 2012 to
Table 1  
Gene signatures included in the nearest-template prediction studies of the GSE14520 (N = 242) and GSE54236 (N = 78) datasets.

| Study          | Year       | Signature names (Molecular Signature Database [MSIGDB])a | Signature name in the study | No. of genes in the signature | Genes covered in GSE14520 | Samples with the signature (GSE14520)b | Genes covered in GSE54236 | Samples with the signature (GSE54236)b |
|----------------|------------|-----------------------------------------------------------|-----------------------------|------------------------------|--------------------------|-----------------------------------------|-------------------------------|----------------------------------------|
| Iizuka et al.  | 2003       | IIZUKA_LIVER_CANCER_EARLY_RECURRENCE_DN                  | Recurrence_Iizuka           | 12                           | 12 (100.0%)              | NA                                       | 12 (100.0%)                  | NA                                      |
| Ye et al.      | 2003       | YE_METASTATIC_LIVER_CANCER                                | Metastasis_Ye               | 28                           | 28 (100.0%)              | NA                                       | 27 (96.4%)                   | NA                                      |
| Lee et al.     | 2004       | LEE_LIVER_CANCER_POOR-SURVIVAL_UP,_DN                   | Lee_OS                      | 360                          | 316 (87.8%)              | 202 (83.5%)                             | 355 (98.6%)                 | 69 (88.5%)                             |
| Korukawa et al.| 2004       | Early_recurrence_signaturec                               | Recurrence_Korukawa         | 19                           | 17 (89.5%)               | NA                                       | 19 (100.0%)                  | NA                                      |
| Kaposi-Novak et al. | 2006    | NOVAK_LIVER_CANCER_MET_UP,_DN                            | MET_Kaposi-Novak            | 24                           | 24 (100.0%)              | 66 (27.3%)                             | 24 (100.0%)                  | 24 (30.8%)                             |
| Boyault et al. | 2007       | BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP,_DN                | G3_Boyault                  | 239                          | 239 (100.0%)             | 192 (79.3%)                             | 239 (100.0%)                 | 64 (82.1%)                             |
| Boyault et al. | 2007       | BOYAULT_LIVER_CANCER_SUBCLASS_G56_UP,_DN                | G56_Boyault                 | 29                           | 29 (100.0%)              | 78 (32.3%)                             | 29 (100.0%)                  | 21 (26.9%)                             |
| Boyault et al. | 2007       | BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP,_DN                | G6_Boyault                  | 84                           | 84 (100.0%)              | 69 (28.5%)                             | 84 (100.0%)                  | 26 (33.3%)                             |
| Wang et al.    | 2007       | WANG_RECURRENT_LIVER_CANCER_UP,_DN                    | Recurrence_Wang             | 36                           | 32 (88.9%)               | 75 (31.0%)                             | 36 (100.0%)                  | 20 (25.6%)                             |
| Cairo et al.   | 2008       | C2_POOR-PROGNOSIS_UP,_DN                               | C2_Cairo                    | 16                           | 16 (100.0%)              | 102 (42.1%)                            | 16 (100.0%)                  | 29 (37.2%)                             |
| Chiang et al.  | 2008       | CHIANG_LIVER_CANCER_SUBCLASS_CTNBN1_UP,_DN             | CTNBN1_Chang                | 346                          | 280 (80.9%)              | 134 (55.4%)                            | 343 (99.1%)                  | 57 (73.1%)                             |
| Chiang et al.  | 2008       | CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP,_DN          | Interferon_Chiang           | 78                           | 57 (73.1%)               | 85 (35.1%)                             | 77 (98.7%)                   | 33 (42.3%)                             |
| Chiang et al.  | 2008       | CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP,_DN      | Proliferation_Chiang        | 357                          | 299 (83.8%)              | 198 (81.8%)                            | 353 (98.9%)                  | 68 (87.2%)                             |
| Coulouan et al. | 2008    | COULOUARIN_LIVER_CANCER_TGF_BETA_LATE_VS_EARLY_UP,_DN  | TGF_B_Coulouan              | 249                          | 215 (86.3%)              | 110 (45.5%)                            | 244 (98.0%)                  | 42 (53.8%)                             |
| Sakai et al.   | 2008       | SAKAI_TUMOR_INFLITRATING_MONOCYTES_UP,_DN              | Monocyte_Sakai              | 108                          | 104 (96.3%)              | 51 (21.1%)                             | 106 (98.1%)                  | 23 (29.5%)                             |
| Woo et al.     | 2008       | WOO_LIVER_CANCERRECURRENCE_UP,_DN                    | Recurrence_Woo              | 185                          | 185 (100.0%)             | 176 (72.7%)                            | 185 (100.0%)                 | 61 (78.2%)                             |
| Yamashita et al. | 2008       | YAMASHITA_LIVER_CANCER_STEM_CELL_UP,_DN                | CSC_Yamashita               | 112                          | 104 (92.9%)              | 143 (58.1%)                            | 112 (100.0%)                 | 42 (53.8%)                             |
| Yamashita et al. | 2008       | YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP,_DN              | EPCAM_Yamashita             | 70                           | 65 (92.9%)               | 135 (55.8%)                            | 68 (97.1%)                   | 32 (41.0%)                             |
| Hoshida et al. | 2009       | HOSHIDA_LIVER_CANCER_SUBCLASS_S3_S1                    | S1_Hoshida                  | 498                          | 492 (98.8%)              | 170 (70.2%)                            | 498 (100.0%)                 | 60 (76.9%)                             |
| Hoshida et al. | 2009       | HOSHIDA_LIVER_CANCER_SUBCLASS_S3_S2                    | S2_Hoshida                  | 379                          | 370 (97.6%)              | 179 (74.0%)                            | 379 (100.0%)                 | 53 (67.9%)                             |
| Yoshio et al.  | 2009       | YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_UP,_DN          | Recurrence_Yoshio           | 105                          | 80 (76.2%)               | NA                                       | 100 (95.2%)                  | NA                                      |
| Andersen et al. | 2010      | ANDERSEN_LIVER_CANCER_KRT19_UP,_DN                   | CK19_Andersen               | 110                          | 96 (87.3%)               | 177 (73.1%)                            | 109 (99.1%)                  | 60 (76.9%)                             |
| Roessler et al. | 2010       | ROESSLER_LIVER_CANCER_METASTASIS_UP,_DN               | Metastasis_Roessler         | 161                          | 148 (91.9%)              | NA                                       | 155 (96.3%)                  | NA                                      |
| Woo et al.     | 2010       | WOO_LIVER_CANCER_Cholangiocarcinoma_LIKE_UP,_DN        | CC_Woo                      | 625                          | 599 (95.8%)              | 205 (84.7%)                            | 616 (98.6%)                  | 67 (85.9%)                             |
| Minguez et al. | 2011       | MINGUEZ_LIVER_CANCER_VASCULAR_INVASION_UP,_DN          | VL_Minguez                  | 35                           | 33 (94.3%)               | 109 (45.0%)                            | 34 (97.1%)                   | 31 (39.7%)                             |
| Chew et al.    | 2012       | Lymphocyte_infiltration_signaturec                     | Lymphocyte_Chew             | 14                           | 14 (100.0%)              | NA                                       | 13 (92.9%)                   | 24 (30.8%)                             |
| Kim et al.     | 2012       | OVERALL_survival_signaturec                            | OS_Kim                      | 65                           | 65 (100.0%)              | 174 (71.9%)                            | 65 (100.0%)                  | 59 (75.6%)                             |
| Roessler et al. | 2012       | Poor_outcome_signaturec                               | G2_Roessler                 | 10                           | 9 (90.0%)                | 35 (14.5%)                             | 10 (100.0%)                  | NA                                      |
| Lim et al.     | 2013       | Disease_free_survival_signaturec                      | DFS_Lim                     | 30                           | 18 (60.0%)               | NA                                       | 26 (86.7%)                   | NA                                      |
| Ko et al.      | 2014       | VDAC1_signaturec                                       | VDAC_Ko                      | 45                           | 45 (100.0%)              | 74 (30.6%)                             | 45 (100.0%)                  | 19 (24.4%)                             |

a MSIGDB: www.broadinstitute.org/gsea/msigdb.
b Samples enriched with good or poor prognosis according to the nearest-template prediction (NTP) method for each gene signature (FDR < 0.05). NA means the NTP method failed to classify any samples for the gene signature.
c Gene signature not included in the MSIGDB database and a brief introduction was provided.
February 2014 at the Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University. Patients were included if they received curative resection surgery for the first time without any previous anti-cancer treatment including chemotherapy or radiotherapy. Patients were excluded if they received palliative treatments, had a distant metastasis, had a history of other malignancies, received a liver transplant or were unwilling to participate in the study. All patients were diagnosed with HCC based on the pathological examination. Personal characteristics and clinicopathological characteristics of the patients were extracted from the medical records and assessed by the clinicians. The results of the preoperative biochemical tests and image evaluations were also retrieved. The resection treatments and surgical procedures were performed following the general guidelines that had been designed according to tumor size, location, and liver functional reserve (Wang et al., 2010a). Patient follow-up was performed by telephone calls or checking the medical records at half-year intervals, and the last follow-up was performed in September 2016.

An independent validation case cohort was recruited from November 2009 to March 2010 in the same hospital (N = 78). The inclusion and exclusion criteria were similar to the previous case cohort. The last follow-up was performed September 2012 with the longest follow-up period extending up to 39 months. Detailed participant information is provided as Supplementary Table 3. Each participant provided written consent, and the institutional review board of the Second Military Medical University approved the study.

2.4. Immunohistochemical (IHC) Staining Methods

For the HCC patients, FFPE tumor tissues were used by the National Engineering Center for Biochip, Shanghai, to construct tissue microarrays (TMAs). For each patient, a 0.75-mm diameter core of the cancer FFPE tissue was punched and arranged in the TMA blocks. Sections of the TMAs (6-μm thick) were used to determine the expression levels of RAD21, CDK1, and HDAC2 following general IHC staining protocols. In brief, the TMAs were deparaffinized with xylene and rehydrated with graded ethanol solutions. To quench endogenous peroxidase activity, the TMA was treated with 3% hydrogen peroxide for 15 min at room temperature. Then, the sections were put into citric acid solution (pH = 6.0) and boiled at 95 °C for 40 min. After cooling, the sections were washed three times with phosphate-buffered saline (PBS) and blocked in 5% fetal bovine serum for 15 min at room temperature. Primary antibodies for CDK1 (1:150; Abcam, USA), HDAC2 (1:200; Abcam), and RAD21 (1:50; Santa Cruz, USA) were used to add to the sections, which were incubated at 4 °C overnight. After washing three times with PBS, the sections were incubated with a peroxidase-polymer labeled rabbit anti-mouse secondary antibody, followed with diaminobenzidine staining to detect peroxidase activity. Finally, the sections were counterstained with hematoxylin and differentiated in hydrochloric acid alcohol, followed by dehydration and mounting.

Expression was assessed by the staining intensity and the distribution of the positive cells. Intensity was categorized as 0–3 (0, negative; 1, weak; 2, moderate; 3, strong), and the distribution of positive cells was grouped as 1, 0–25%; 2, 25–50%; 3, 50–75%; and 4, >75%. The immunoreactive score (IRS) was calculated by multiplying the intensity with the distribution of positive cells (Wang et al., 2012), and the median IRS score was applied to categorize the HCC patients into high and low protein expression levels.

2.5. Construction of the PPI Network

For those gene signatures significantly that were associated with the prognosis of the HCC patients in both case cohorts, PPI networks for these genes were constructed with the Reactome FI plugin of the Cytoscape software (Version 3.2.0; http://www.cytoscape.org/) (Shannon et al., 2003; Wu et al., 2010). With the Network Analyzer plugin (Version 1.0; http://med.bioinf.mpi-inf.mpg.de/netanalyzer/) (Assenov et al., 2008), the basic topological parameters, including the degree of node distribution, the shortest path length distribution, and the average clustering coefficient distribution were assessed.

2.6. Cell Culture and siRNA Transfection Methods

The human liver cancer cell lines Hep3B, SMMC-7721 and Huh-7 were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). The CQST-2 cell line, which was derived from the portal vein tumor thrombi (PVTT) of an HCC patient and established by Dr. Cheng's lab (Wang et al., 2010b), was kindly provided by Dr. Cheng's lab. All cell lines were cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal bovine serum, 100 μg/mL of streptomycin, 4.5 mg/mL of d-glucose, 300 mg/L of L-glutamine, and 110 mg/L of sodium pyruvate. The cell lines were maintained in an incubator with a humidified atmosphere of 5% CO2 at 37 °C.

In the siRNA transfection assays, 5 x 104 cells/well were plated in 6-well cell culture plates. The siRNA duplexes for CDK1, RAD21, and HDAC2 or the scramble control were synthesized by GenePharma (Shanghai, China) and were transfected with Lipofectamine 2000 reagent (Life Technologies, USA) at a concentration of 40 nmol/L following the manufacturer’s guidelines. After 48 h, the endogenous protein levels in the transfected cells were determined by Western blotting.

2.7. Determination of Cell Viability and Proliferation

Cells (2000 cells/well) were plated in 96-well plates, and 24 h later, the siRNA duplexes for CDK1, RAD21, and HDAC2 or the scramble control were transfected into CQST-2 cells (40 nmol/L). 24, 48 and 72 h after transfection, the CCK-8 solution was added to the cells, and the preparations were incubated for another 4 h before the absorption values (450 nm) were determined.

To determine the anti-cancer activities of the CDK1 selective inhibitor RO-3306 (Selleck, China), liver cancer cells (3000 per well) were plated in 96-well plates. After 24 h, RO-3306 was added to the cells at concentrations of 0 (vehicle, DMSO), 0.78, 1.56, 3.13, 6.25, 12.5, or 25 μM. The cells were cultured for another 48 h, and CCK-8 solution was applied to determine the cellular viability following the manufacturer’s guidelines. To determine the anti-proliferation activity of RO-3306, liver cancer cells (3000 per well) were plated in 96-well plates, and the vehicle (DMSO) or RO-3306 (12.5 μM) was added; after 24, 48, or 72 h, CCK-8 was applied to determine the cellular proliferation.

2.8. Western Blotting Methods

Cells were lysed with radio-immunoprecipitation assay (RIPA) buffer containing a cocktail of protease inhibitors (Sigma, USA). Protein concentrations were measured by the bicinchoninic acid assay (Sigma, USA), and total protein (30 μg) was separated on 10% SDS-PAGE gels and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). Membranes were blocked with 5% skim milk for 1 h and then probed overnight at 4 °C with the same antibodies as in the IHC staining tests. After washing 3 times, the PVDF membranes were incubated with secondary horseradish peroxidase-linked secondary antibody for 1 h at room temperature. The signaling intensity was determined with an enhanced chemiluminescence detection reagent and visualized with X-ray films.

2.9. Statistical Analyses

To determine the prognostic effects of the gene signatures, the nearest template prediction (NTP) method implemented in the Gene Pattern software (Broad Institute of Harvard and MIT, Boston, MA) was used to make class prediction of the HCC patients based on the gene-expression data and the list of signature genes (Hoshida, 2010). Templates of the “good prognosis” and “good prognosis” patterns for
each gene signature were defined as those genes associated with worse or better outcomes, respectively. Subjects closer to “poor” or “good” prognosis templates with a false discovery rate (FDR) < 0.05 were classified as poor or good outcome, respectively. Those with the FDR > 0.05 were recognized as an unclassified group. Cramer's V test was calculated to test the concordance rate of the prediction class for the patients by the gene signatures (Fan et al., 2006). Values < 0.40 indicated a weak correlation between the gene signatures, values between 0.40 and 0.60 indicated substantial correlation, and values > 0.60 indicated strong correlation. Kaplan-Meier plots, together with the log-rank tests, were applied to identify gene signatures that were associated with the OS of the patients. Univariate Cox regressions were applied to determine the associations between the basic characteristics or the gene signatures and OS of the patients. Due to the collinearity for the variables of the characteristics and the NTP prediction outcomes, the associations between the variables and OS of patients were assessed with the random survival forest method, which was developed for right-censored data (Ishwaran and Kohagaru, 2010). Variable importance was assessed with the variable importance (VIMP) measures for individual factors in the random survival forests model (Ishwaran and Kohagaru, 2010). A positive VIMP value indicated that the misspecification detracted from the predictive accuracy in the forest for the variables and that the predictive power of the forest depended on these variables. Zero or negative VIMP values suggested that the variables contributed nothing to predictive accuracy or even contributed noise to the prediction models and that these variables should be filtered out from the models. In the random survival forest, 5000 trees were grown using a log-rank, score-splitting algorithm. For evaluations, the VIMP for each variable was recorded. The analysis was independently repeated 100 times, and the VIMP was averaged for each variable.

For the TMA cohorts from the Eastern Hepatobiliary Surgery Hospital, univariate Cox regressions were performed to evaluate the basic characteristics and the IHC scores of the biomarkers that were associated with OS. Backward stepwise multivariate Cox regression analyses were performed to identify the independent factors that contribute to the OS of HCC patients. Only significant factors in the univariate analyses were introduced into the multivariate Cox model.

Differences in demographic characteristics and selected variables were evaluated with the χ² test (for categorical variables) or Student's t-test (for continuous variables). Comparisons between the multiple groups were performed using one-way ANOVA to determine the overall significance. The data are presented as the means ± SEM, unless otherwise indicated. All analyses were performed with R software (Version 3.3.1; www.r-project.org) and related packages, and P < 0.05 for two-sided tests was recognized as statistically significant.

3. Results

3.1. The Nearest Template Prediction Results for HCC Patients

A total of 30 gene signatures were identified that might be associated with the prognosis for HCC patients (Table 1). The number of genes ranged from 10 to 625, and 60% to 100% of these genes were covered by platforms GSE14520 and GSE54236 (Table 1). For each dataset, 23 of the 30 gene signatures successfully classified the HCC patients into poor or good outcomes (FDR P < 0.05). The number of patients enriched with the gene signature ranged from 35 (14.5%) to 205 (84.7%) in GSE14520 and from 19 (24.4%) to 69 (88.5%) in GSE54236 (Table 1). The NTP prediction results are provided in Fig. 1. Cramer's V test suggested that there were three major groups for the prediction results of the gene signatures in the two cohorts (Fig. 1b and d). The first class contained mainly gene signatures that indicated the progenitor tumor cell origin (CSC_Yamashita (Yamashita et al., 2008), EPCAM_Yamashita (Yamashita et al., 2008), CK19_Andersen (Andersen et al., 2010), S2_Hoshida (Hoshida et al., 2009) and C2_Cario (Cairo et al., 2008)); cellular proliferation (Proli_Chiang (Chiang et al., 2008)); and vascular invasion (VI_Minguez (Minguez et al., 2011)). The second class contained those gene signatures of TGF-beta_Coulouni (Coulouni et al., 2008), MET_Kaposi-Novak (Kaposi-Novak et al., 2006), G3_Boyault (Boyault et al., 2007), S1_Hoshida (TGF-WNT) (Hoshida et al., 2009), Recurrence_Woo (Woo et al., 2008), and OS_Kim (Kim et al., 2012). The third class contained the gene signatures of CTTNB1_Chiang (Chiang et al., 2008), Interferon_Chiang (Chiang et al., 2008), G8_Boyault (CTTNB1_WNT activation) (Boyault et al., 2007), and G5_6_Boyault (CTTNB1_WNT activation) (Boyault et al., 2007).

3.2. Association of Gene Signatures With the OS of HCC Patients

In dataset GSE14520, the univariate Cox analyses showed that tumor size, nodular number (multiple vs. single), cirrhosis, AFP level, BCLC stage, CLIP stage and TNM stage were associated with the OS of the patients (Table S1). Of the 23 gene signatures in GSE14520, 15 were associated with the OS of the HCC patients, as indicated by Kaplan-Meier plots and log-rank tests (Figs. 1 and 2). For GSE54236, the univariate Cox analyses indicated that the doubling time for HCC was associated with the OS of HCC patients (Table S1). Kaplan-Meier plots showed that, in dataset GSE54236, 12 gene signatures were associated with the OS of the HCC patients (Figs. 1 and 3). Univariate Cox analyses for the gene signatures that categorized HCC groups (poor or unclassified vs. good) are provided as Table S2. Eight and 11 gene signatures were not associated with the OS of HCC patients in GSE14520 (Fig. S1) and GSE54236 (Fig. S2), respectively. Overall, 11 gene signatures were associated with the OS for HCC patients in both case cohorts (Table S3).

To test the prognostic performance of the gene signatures, a random survival forest algorithm was applied to determine the VIMP values of the basic characteristics and the gene signatures (Fig. 4). In GSE14520, the top-ranked variables after 100 runs were BCLC stage; TNM stage; CLIP stage; cirrhosis status; and gene signatures including Recurrence_Wang (Wang et al., 2007), OS_Lee (Lee et al., 2004), CK19_Andersen (Andersen et al., 2010), Monocyte_Sakai (Sakai et al., 2008), CC_Woo (Woo et al., 2010), MET_Kaposi-Novak (Kaposi-Novak et al., 2006), and EPCAM_Yamashita (Yamashita et al., 2008). For GSE54236, the variables in the random survival forests with positive VIMP values were MET_Kaposi-Novak (Kaposi-Novak et al., 2006), G3_Boyault (Boyault et al., 2007), Proli_Chiang (Chiang et al., 2008), doubling time, CSC_Yamashita (Yamashita et al., 2008), CK19_Andersen (Andersen et al., 2010), CC_Woo (Woo et al., 2010), and TGF-β_Coulouni (Coulouni et al., 2008). These results suggest that gene signatures have higher predictive values than conventional factors in predicting of the OS of HCC patient.

3.3. Construction of the Functional PPI Network

For the 11 gene signatures that were significantly associated with the OS of HCC patients, 1626 individual genes were covered. With the ReactomeFDR plugin in the Cytoscape, a PPI network was constructed with 1406 nodes and 10,135 edges (Fig S3a). The topological analysis of the PPI network suggested that these 11 gene signatures constituted a scale-free biologic saling network (Fig S3b-3c). The top-ranked non-linker nodes included EP300, RPS27A, CDK1, RAD21, RPS27, HDAC2, and CTNNB1; the top-ranked linker nodes were UBC, MYC, JUN, SP1, PLK1, EED, ACTB, RXRA, and STAT3 (degree > 90). A simplified PPI network with those genes of node degree > 60 is provided in Fig. 5. We hypothesized that the core genes in the networks may have prognostic significance for HCC patients. Because transcription coactivator EP300 and ribosomal proteins RPS27A and RPS27 are not ideal biomarkers or therapeutic targets for HCC, CDK1, RAD21, and HDAC2 were chosen for subsequent analysis because they had relatively high degrees in the PPI network.
3.4. Expression Patterns of Potential Prognostic Biomarkers in HCC Tissues

We constructed TMAs for HCC patients to determine the prognostic values of the core genes with the IHC staining method (N = 60). Detailed patient clinical information is provided in Table S3. We found that the expression levels of CDK1, HDAC2 and RAD21 were increased in tumor tissues compared with the adjacent normal tissues (Fig. 6a). CDK1 was expressed in the cytoplasm of the cancer cells, but no expression was evident in normal tissues (Fig. S4; Wilcoxon test, P < 0.001). Higher expression of CDK1 was associated with worse outcomes for HCC patients (log-rank test, P = 0.001; Fig. 6b). HDAC2 was expressed in the cytoplasm of tumor cells and was overexpressed in HCC tissues (Fig. S4; Wilcoxon test, P < 0.001). Higher expression correlated with poorer OS of HCC patients (log-rank test, P = 0.001; Fig. 6b). RAD21 was immunoreactive mainly in the nuclei of HCC cells (Fig. S4); only weak nuclear staining of RAD21 was evident in normal liver cells (Wilcoxon test, P = 0.001). Higher nuclear staining of RAD21 in HCC cells correlated with worse OS of HCC patients (log-rank test, P = 0.026; Fig. 6b). The univariate analyses of the clinical characteristics and the IHC scores of CDK1, HDAC2, and RAD21 are provided in Table 2. Multivariate Cox analyses showed that CDK1 level, tumor size, and satellite nodule status were independent prognostic factors for the OS of HCC patients (Table 2).

We further validated the prognostic values of CDK1 in an independent case cohort (N = 78; Table S3). HCC patients with higher CDK1 levels were associated with poor OS compared with those have lower CDK1 level, as suggested by the log-rank test (P = 0.006; Fig. S5). The multivariate Cox analyses also suggested that CDK1 was also an independent risk factor for HCC patients in the validation cohort (Table S4).

3.5. CDK1 is a Potential Therapeutic Target for HCC

The specificity of the antibodies for the IHC staining and the roles of these proteins in HCC progression were confirmed with siRNA methods in cell models. Knockdown of CDK1, RAD21, and HDAC2 with siRNAs led
Fig. 2. Kaplan-Meier plots and log-rank tests for the 15 gene signatures that are associated with the overall survival of HCC patients in GSE14520.
to reduced proliferation of CSQT-2 cells (Fig. S6a). Knockdown of RAD21 reduced the levels of CDK1, but not HDAC2. Knockdown of HDAC2 did not affect the protein expression of CDK1 or RAD21 (Fig. S6b). These results indicate that RAD21 might regulate the CDK1 activity in HCC tumor cells.

Because CDK1 was an independent prognostic factor for HCC, we determined whether CDK1 could be a therapeutic target for HCC. An inhibitor (RO-3306) of CDK1 significantly reduced cellular viability (Supplementary Fig. 6c) and proliferation (Supplementary Fig. 6d) for HCC cell lines, including Hep3B, SMMC-7721, Huh-7 and CSQT-2, suggesting that CDK1 could be a target for HCC treatment.

4. Discussion

An analysis of the biological features of HCC is necessary for personalized therapy. Various studies have reported molecular classifications and prognostic molecular signatures for HCC based on the gene expression from HCC tissues or adjacent non-tumoral tissues, which have revealed the tumor heterogeneity [15-42]. With the NTP methods, we determined the prognostic effects of the reported gene signatures in tumor tissues and found that the predictive roles of these gene signatures were reproducible between the datasets. With the random forest survival method, we compared the VIMP values for gene signatures and clinical factors and found that the gene signatures were superior to the clinical characteristics of patients, such as tumor size, nodular status, and the cirrhosis status, for GSE14520 and the doubling time for GSE54236, indicating the values of gene signatures in the prognostic prediction of HCC patients. Interestingly, the gene signatures that were associated with the OS of the patients were in high concordance, and the genes from the signatures were functionally linked with each other. These results suggest that the predictive abilities for the gene signatures are reproducible and that they might contribute to personalized prognosis prediction for HCC patients.

Based on 287 HCC patients, Villanueva et al. determined the predictive effects of early recurrence for 18 gene signatures derived from HCC tissues and 4 from adjacent non-tumoral tissues (Villanueva et al., 2011).
The genomic gene expression profiling was determined for FFPE tumor specimens and adjacent tissues, and the NTP method was applied to identify those patients with a tendency for early recurrence. They found that only the G3_Boyault gene signature (Boyault et al., 2007), derived from HCC tissues, and another gene signature generated in adjacent non-tumor cirrhotic tissues (Hoshida et al., 2008) were significantly associated with early recurrence or overall recurrence for HCC patients. However, the other 17 tumor-derived gene signatures were not associated with recurrence. Our current study examined the associations between the prediction results of the gene signatures and the recurrence of HCC patients in GSE14520 and found that only gene signature OS_Kim (Kim et al., 2012) was associated with recurrence (data not shown). However, we demonstrated that ten of these gene signatures were predictors for the OS of HCC patients in two independent case cohorts, GSE14520 and GSE54236. These results indicate that, these gene signatures have promising predictive effects for the OS of HCC patients but not for the risk of recurrence. Although disease recurrence is a prognostic factor for the death of HCC patients, other clinical factors and treatment methods also contribute to survival. In future studies, gene signatures that confer the recurrence risk and gene signatures derived from the tumor microenvironment that are associated with the prognosis for HCC patients need to be identified.

Although there were few overlapping genes among the 11 gene signatures (data not shown), they formed a tightly linked, scale-free biological PPI network, as suggested by the node degree distribution following a power algorithm (Barabasi and Oltvai, 2004). We hypothesized that the core genes with high degrees in the network might have important biological functions in the signaling transduction and that their expression levels might have prognostic values. With the in-house HCC tissue samples, the prognostic values for these genes were determined. The expression levels of the core genes RAD21, HDAC2, and CDK1 were increased in HCC tissues compared with adjacent non-tumor tissue, and their expression levels were associated with the OS of HCC patients. As determined with multiple Cox analyses, CDK1, but not RAD21 or HDAC2, when adjusted for clinical characteristics, was an independent prognostic factor for HCC patients.

For various cancer types, HDAC2 acts as an oncogene through the epigenetic regulation of genes and the corresponding signaling cascades in cancer development, and HDAC2 expression is gradually increases, from pre-neoplastic lesions, to low-grade dysplastic nodules, high-grade dysplastic nodules, and HCCs (Nam et al., 2005). Higher HDAC2 levels are correlated with poor survival of HCC patients (Ler et al., 2015; Quint et al., 2011), which is consistent with results of the current study. In HCC cells, inhibiting of HDAC2 disrupts the G1/S phase of the cell cycle and leads to apoptosis through upregulating the total p21, p27, and acetylated p53 levels and reducing CDK6 and BCL2 levels (Lee et al., 2014; Noh et al., 2011); these results suggest that HDAC2 could be a therapeutic target for HCC. In a murine xenograft model, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles reduced the growth of human HCC (Lee et al., 2014); however, this...
Fig. 5. The core functional PPI network derived from the 11 gene signatures that were significantly associated with the overall survival of HCC patients (genes with node degree > 60). The red nodes are genes included in the gene signature, and degree nodes are linker genes in the network construction derived from the Reactome FI plugin of Cytoscape. The size of the node correlates with the degree of the indicated gene in the network. CDK1, HDAC2, RAD21, EP300, RPS27A and RPS27 were genes with the top-ranked degrees.

Fig. 6. The protein expression levels of RAD21, CDK1, and HDAC2 in tumor and adjacent normal HCC tissues and their associations with overall survival (OS) for HCC patients. (a) CDK1, HDAC2, and RAD21 were significantly increased in HCC tissues compared with adjacent normal tissues (Wilcoxon signed rank test, P < 0.001). (b) Higher expression levels of CDK1 (log-rank test, P = 0.001), HDAC2 (log-rank test, P = 0.014), and RAD21 (log-rank test, P = 0.027) in the HCC tissues were associated with worse OS of the patients compared with lower expression levels.
method is far from clinical use. Two small molecule inhibitors of HDACs (HDACis), SAHA (vorinostat) and FK-228 (romidepsin), have been approved by the U.S. Food and Drug Administration (FDA) to treat refractory cutaneous and peripheral T cell lymphoma (West and Johnstone, 2014). In addition to these agents, >20 different HDACis have produced encouraging results for the treatment of hematological malignancies, including Hodgkin’s lymphoma, multiple myeloma, and acute myeloid leukemia; however, the therapeutic effects of HDACis on solid tumors have been disappointing (West and Johnstone, 2014). In addition to toxicity, the off-target actions of the HDACis may lead to treatment failure for solid tumors. Thus, inhibitors that are selective for HDAC2 should be developed, and their therapeutic effects in HCC patients need to be addressed.

RAD21, a component of the cohesion complex, is essential for chromosomal segregation during the metaphase–anaphase transition of mitosis (Xu et al., 2004). RAD21 is also involved in homologous recombinational repair or the error-free repair of DNA damage, which could influence the sensitivity of gastrointestinal and breast cancers to radiotherapy or chemotherapy (Xu et al., 2010; Xu et al., 2011). High levels of nuclear RAD21 staining correlate with poor disease-specific survival of colorectal cancer patients with KRAS mutations (Deb et al., 2012) and with early relapse in patients with high-grade luminal, basal, or HER2 breast cancers (Xu et al., 2011). However, the roles of RAD21 in HCC development and progression have not been determined. In the current study, we found that nuclear RAD21 was increased in HCC tissues compared with adjacent non-tumor tissues, and higher RAD21 levels were associated with shorter OS of HCC patients. In HCC cells, RAD21 knockdown reduced cellular proliferation and down-regulated CDK1 levels, which might partially underlie the RAD21 oncogenic activities in HCCs. These results suggest that RAD21 could be a biomarker or therapeutic target for HCC patients and that the potential intervention methods need to be developed.

Table 2
Univariate and multivariate analysis of the clinical and pathological characteristics for the overall survival of HCC patients (N = 60).

| Characteristics | Univariate analysis | | | Multivariate analysis | | |
|-----------------|---------------------|----------------|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | HR (95% CI) | P-value | HR (95% CI) | P-value | | | | |
| Age, per year   | 0.98 (0.94–1.02) | 0.258 | | | | | | |
| Sex (Male vs. Female) | 0.77 (0.29–2.04) | 0.599 | | | | | | |
| HbeAg (Positive vs. Negative) | 0.84 (0.32–2.23) | 0.727 | | | | | | |
| Tumor diameter (>3 vs. ≤3 cm) | 3.73 (1.12–12.45) | 0.033 | 3.62 (1.02–12.79) | 0.046 | | | | |
| Multiple nodules (Yes vs. No) | 5.06 (2.14–7.79) | <0.001 | 5.48 (2.09–14.37) | <0.001 | | | | |
| Tumor encapsulation | | | | | | | | |
| Complete vs. Absence | 0.58 (0.23–1.47) | 0.25 | | | | | | |
| Incomplete vs. Absence | 0.53 (0.20–1.38) | 0.192 | | | | | | |
| Cirrhosis (Child-Pugh B vs. C vs. A) | 2.17 (1.32–3.58) | <0.001 | | | | | | |
| Tumor differentiation (II vs. I) | 2.65 (0.70–9.57) | 0.248 | | | | | | |
| Microscopic vascular invasion (Yes vs. No) | 3.27 (1.47–7.24) | 0.004 | 2.12 (0.94–4.75) | 0.069 | | | | |
| BCLC stage (B vs. C vs. A) | 4.56 (2.09–9.93) | <0.001 | | | | | | |
| AFP (≥20 vs. ≤20 ng/mL) | 2.93 (1.01–8.53) | 0.048 | | | | | | |
| γ-GT (≥50 vs. ≤50 U/L) | 2.87 (0.99–8.35) | 0.053 | | | | | | |
| RAD21 (High vs. Low) | 2.49 (1.08–5.76) | 0.033 | | | | | | |
| HDAC2 (High vs. Low) | 3.21 (1.21–8.53) | 0.019 | | | | | | |
| CDK1 (High vs. Low) | 3.93 (1.65–9.39) | 0.002 | 4.05 (1.61–10.03) | 0.003 | | | | |

Abbreviations: AFP, α-fetoprotein; HR, hazard ratio; 95% CI, 95% confidence interval; BCLC, Barcelona Clinic Liver Cancer stage; γ-GT, γ-glutamyl transpeptidase.

CDK1 is a cyclin-dependent kinase that plays critical roles in the regulation of cellular mitosis. Depending on its association with cyclin A or B, it participates in the progression of the G1/S and G2/M phases of the cell cycle through the phosphorylation of various substrates, including Ajuba (Chen et al., 2016), CDP/Cnx (Santaguida et al., 2001), Bcl2 (Vantieghem et al., 2002), and Wee1 (Harvey et al., 2005) (Petrone et al., 2016). Quantitative phosphoproteomics has identified >500 candidate substrates for CDK1; these substrates are associated with genes that are G2 and M phase-specific (Petrone et al., 2016). In addition to its roles in mitosis, CDK1 also participates in the regulation of self-renewal, differentiation, and somatic reprogramming of human embryonic stem cells (Wang et al., 2017). CDK1 also stimulates the enzymatic activity of SIRT3, which enhances mitochondrial function and tumor radioresistance (Liu et al., 2015). Hyperactivation of CDK1 is associated with poor prognosis for patients with lung adenocarcinoma (Shi et al., 2016), ovarian cancer (Yang et al., 2016), renal cell carcinoma (Hongo et al., 2014), and breast cancer (Pavlou et al., 2014). For lymphomas, hepatoblastomas, and breast cancers, the inhibition of CDK1 downregulates survivin expression and induces MYC-dependent apoptosis (Goga et al., 2007; Kang et al., 2014). In the current study, we found that CDK1 was detectable in HCC cells but not in normal liver tissues and that high CDK1 independently correlated with short OS. Considering its biological roles, CDK1 expression in HCC cells might reflect proliferation status and cancer stem cell properties, which are associated with the OS of HCC patients (Fig. 1b and d). As determined with cultured cells, CDK1 knockdown or inhibition correlated with reduced cellular proliferation, suggesting that CDK1 is a therapeutic target for HCC. Various inhibitors of CDK1, including flavopiridol, BMI-1026, olomoucine, staurosporine, and RO-3306 have been developed, and some have entered phase I and II clinical trials for the treatment of a variety of solid tumors and hematologic malignancies (Wang et al., 2011). For most of these inhibitors, however, their selective activity is poor; they generally inhibit CDK1, 2, 4, and 6 with equal potency (Wang et al., 2011). As shown in early clinical trials, these inhibitors often lead to high toxicity. Selective CDK1 inhibitors can exert more favorable therapeutic effects. For example, a selective CDK1 inhibitor, RO-3306, induces cell cycle arrest and apoptosis in cancer cells but has minimal effects on normal cells (Vassilev et al., 2006). In the current study, RO-3306 reduced the proliferation of cultured HCC cells. However, whether selective inhibitors for CDK1 could act as monotherapy agents or show synergistic effects with other chemotherapeutic agents needs to be addressed.

In conclusion, we evaluated the prognostic capacity of 30 gene signatures and found that 11 were significantly associated with the OS of HCC patients in two HCC cohorts. The genes from the 11 signatures consisted of a scale-free functional PPI network. The protein expression levels of the core nodes, RAD21, CDK1, and HDAC2, had prognostic value for HCC patients; however, only CDK1 was an independent prognostic factor. Further, because inhibition of CDK1 showed promising anticancer activity, it could serve as a therapeutic target for HCCs. In summary, the results provide potential biomarkers for the prediction of prognosis and present potential targets for the treatment of HCC patients. However, more studies are warranted to determine the roles of these proteins and to develop novel therapeutics for HCC.
Funding
The work was financially supported by the by grants from the Ministry of Science and Technology of the People’s Republic of China (2014AA020524), the Special Research Fund of Ministry of Health for Non-Profit Sector (201302010), the National Nature Science Foundation (81302507), the Science and Technology Commission of Shanghai Municipality (14391901800), and the Shanghai Municipal Commission of Health and Family Planning (2016Y0250, 2015ZB0202). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of Interest
The authors have declared that no competing interests exist.

Author Contributions
P.C.X.Z. and J.Z. contributed to the study concept and design; P.C.J.Z. and X.Z. obtained funding and provided the essential materials; J.C.L., B.L., Y.Z., X.F. M.Z. and S.L. performed the experiments; X.J., J.Z. and J.W. analyzed the data; P.C. and X.Z. wrote the manuscript. All authors reviewed and approved the final manuscript.

Acknowledgements
None.

Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ebiom.2017.04.014.

References
Andersen, J.B., Loi, R., Perra, A., Factor, V.M., Ledda-Columbano, G.M., Columbano, A., Thorgeirsson, S.S., 2016. Prognostic-derived hepatocellular carcinoma model in the rat. Hepatology 51, 1401–1409.
Assenov, Y., Ramirez, F., Schelhorn, S.E., Lengauer, T., Albrecht, M., 2008. Computing topological parameters of biological networks. Bioinformatics 24, 282–284.
Barabasi, A.L., Oltvai, Z.N., 2004. Network biology: understanding the cell’s functional organization. Nat. Rev. Genet. 5, 101–113.
Boyault, S., Rickman, D.S., de Reynies, A., Balabaud, C., Rebouissou, S., Jeannot, E., Herault, J., 2015. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma. Semin. Liver Dis. 35, 329–338.
Cai, J., Chaudhary, M., El-Fattah, M.A., Aboelmagd, M., Elhamouly, M., 2017. Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: a US population-based study. J.pn. European Gastroen. J. 3, 225–235.
El-Serag, H.B., 2012. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142, 1264–1273, e1261.
Fan, C., Oh, D.S., Wessels, L., Weigelt, B., Nuyten, D.S., Nobel, A.B., van’t Veer, L.J., Perou, C.M., 2006. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355, 560–569.
Fridman, W.H., Pages, F., Sautès-Fridman, C., Galon, J., 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 238–306.
Goga, A., Yang, D., Tward, A.D., Morgan, D.O., Bishop, J.M., 2007. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 13, 820–827.
Harvey, S.L., Charlet, A., Haas, W., Cygi, S.P., Kellogg, D.R., 2005. CDK1-dependent regulation of the mitotic inhibitor Weel. Cell 122, 407–420.
Hongo, F., Takaha, N., Oishi, M., Ueda, T., Nakamura, T., Naitoh, Y., Naya, Y., Kamoi, K., Okihara, K., Matsuhashita, T., et al., 2014. CDK1 and CDK2 activity is a strong predictor of renal cell carcinoma recurrence. Urol. Oncol. 32, 1240–1246.
Hoshida, Y., 2010. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PloS One 5, e11543.
Hoshida, Y., Nijman, S.M., Kobayashi, M., Chan, J.A., Brunet, J.P., Chiang, D.Y., Villanueva, A., Newell, P., Beda, K., Hashimoto, M., et al., 2009. Integrative transcriptome analysis reveals common molecular subclasses of hepatocellular carcinoma. Cancer Res. 69, 7385–7392.
Hoshida, Y., Villanueva, A., Kobayashi, M., Peix, J., Chiang, D.Y., Camargo, A., Gupta, S., Moore, J., Wrobel, M.J., Lermer, J., et al., 2008. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995–2004.
Iizuka, Y., Okita, M., Yamada, M., Nishida, M., Maeda, N., Takao, T., Tamesa, T., Tangoku, A., Tabuchi, H., et al., 2003. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curettage resection. Cancer 98, 923–929.
Intaraprasong, P., Sirimalopiwat, S., Vilaichone, R.–K., 2016. Advances in Management of Hepatocellular Carcinoma. Asian Pac. J. Cancer Prev. 17, 3697–3703.
Ishwaran, H., Kogarul, U.B., 2010. Consistency of random forest survivals. Stat. Probab. Lett. 80, 1056–1064.
Kang, J., Sergio, C.M., Sutherland, R.L., Musgrove, E.A., 2014. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lytic to MYC-dependent human breast cancer cells. BMC Cancer 14, 32.
Kapoor-Novak, P., Lee, J.S., Gomez-Quiroz, L., Coulouarn, C., Factor, V.M., Thorgeirsson, S.S., 2006. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 116, 1582–1595.
Kim, J.S., Lee, J.H., Cho, J.S., Park, H.K., Chang, S.K., Kim, S.B., Park, S.K., Jang, J., Jang, J.H., Lee, S.K., Song, H.Y., Yoon, H.K., 2012. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55, 1443–1452.
Ko, J.H., Gu, W., Lim, I., Zhou, T., Bang, H., 2014. Expression profiling of mitochondrial voltage-dependent anion channel-1 associated genes predicts recurrence-free survival in human hepatocarcinomas. PloS One 9, e110944.
Koren, S., Bentjes-Aijt, M., 2015. Breast tumor heterogeneity: source of fitness, hurdle for therapy. Mol. Cell 60, 537–546.
Kudo, M., Chung, H., Osaki, Y., 2003. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JS score). J. Gastroenterol. 38, 207–215.
Kurokawa, Y., Matoba, R., Takenaka, I., Nagano, H., Dono, K., Nakamori, S., Umeshita, K., Sakane, M., Ueno, M., Ohgane, J., 2004. Molecular biological prediction of early recurrence in hepatocellular carcinoma. J. Hepatol. 40, 284–291.
Lee, J.S., Chu, I.S., Park, Y.K., Kim, S.C., Kim, S.B., Park, E.S., Lim, J.Y., Jeo, H., Kim, Y.J., et al., 2012. Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55, 1443–1452.
Li, K., Calle, I., Albiges, J.L., Manley, J., de Padgett, M., Goedecke, U., et al., 2013. Antitumor effects in hepatocarcinoma of the mitotic inhibitor Weel. Cell 122, 407–420.
Lee, Y.S., Leung, C.H., Lin, W.D., Guo, S.L., Tse, T., Chiu, A., Lam, D.T., Lee, K., et al., 2013. HDAC1-mediated SIRT3 activation enhances mitochondrial function and survival in hepatocellular carcinoma. Carcinogenesis 34, 284–291.
Lee, Y.H., Seo, D., Choi, K.J., Andersen, J.B., Won, M.A., Kitade, M., Gomez-Quiroz, L.E., Judge, A.D., Marquardt, J.U., Raggi, C., et al., 2014. Antitumor effects in hepatocarcinoma of the mitotic inhibitor Weel. Cell 122, 407–420.
Liu, R., Fan, M., Candas, D., Qin, L., Zhang, X., Eldridge, A., Zou, J.X., Zhang, T., Juma, S., Jin, C., et al., 2015. CDK1-mediated SIRT3 activation enhances mitochondrial function and tumor radiosensitivity. Mol. Cancer Ther. 14, 2090–2102.
Luo, J.M., Rui, C., Shi, X., Song, H., Zhao, S., Liu, X., Yang, L., et al., 2016. Prognostic factors in hepatocellular carcinoma: the BCLC classification. Semin. Liver Dis. 19, 329–338.
Marrero, J.A., Kudo, M., Bronowicki, J.P., 2010. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist 15 Suppl. 4, 25–33.
Minguez, M., Hoshida, Y., Villanueva, A., Toffanin, S., Cabellos, L., Thung, S., Mandelk, J., Sia, D., April, C., Fan, J.B., et al., 2011. Gene-expression signature of vascular invasion in hepatocellular carcinoma. J. Hepatol. 55, 1325–1331.
Nam, S.W., Park, J.Y., Ramsamy, S., Shevade, S., Islam, A., Long, P.M., Park, C.K., Park, S.E., Kim, Y.W., Lee, S.H., et al., 2009. Molecular changes from hepatic nodular to hepatocellular carcinoma through gene expression profiling. Hepatology 42, 809–818.
No-author-listed (1998). A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28, 751–755.

Noh, J.H., Jung, K.H., Kim, J.K., Eun, J.W., Bae, H.J., Xie, H.J., Chang, Y.C., Kim, M.G., Park, W.S., Lee, J.Y., et al., 2011. Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 6, e28107.

Noh, J.H., Kim, T.S., Ahn, K.S., Kim, Y.H., Kang, K.J., 2016. Prognostic factors after hepatic resection for the single hepatocellular carcinoma larger than 5 cm. Ann Surg Treat Res 91, 104–111.

Okamoto, M., Utsunomiya, T., Wakiyama, S., Hashimoto, M., Fukuzawa, K., Ezaki, T., Hanai, T., Inoue, H., Mori, M., 2006. Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients. Ann. Surg. Oncol. 13, 947–954.

Osehra, H., Petrusch, U., Helbing, D., Schmidt, J., Mehrafi, A., Schober, G., Guies, A., Abdel-Rahman, O., 2017. Prognostic value of site-specific extra-hepatic disease in hepatocellular carcinoma: a SEER database analysis. Expert Rev Gastroenterol Hepatol 1–7.

Pavlov, M.P., Dimitromanolakis, A., Martinez-Morillo, E., Smid, M., Pofekens, J.A., 2013. A review of hepatocellular carcinoma (HCC) treatment. World J. Surg. Oncol. 11, 386.

Subramaniam, S., Kelley, R.K., Venook, A.P., 2013. Phosphorylation of Bcl-2 in G2/M phase-arrested cells following photodynamic therapy with hypericin involves a CDK1-mediated signal and delays the onset of apoptosis. J. Biol. Chem. 277, 37718–37731.

Vassilev, L.T., Tovar, C., Chen, S., Knezevic, D., Zhao, X., Sun, H., Heimbrook, D.C., Chen, L., 2006. Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. Proc. Natl. Acad. Sci. U. S. A. 103, 10660–10665.

Villa, E., Critelli, R., Lei, B., Marzocchi, G., Camma, C., Giannelli, G., Pontisso, P., Capibbi, G., Enea, M., Cololi, S., et al., 2016. Neangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65, 861–869.

Villanueva, A., Chiang, D.Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Royaute, S., Minguez, B., Sole, M., et al., 2008. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135, 1972–1983.

Villanueva, A., Hoshiada, Y., Battiston, C., Tovar, V., Sia, D., Alsinet, C., Cornella, H., Liberson, A., Kobayashi, M., Kumada, H., et al., 2011. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501–1512.

Wang, K., Liu, Y., Yan, Z.L., Li, J., Shi, L.H., Cong, W.M., Xia, Y., Zou, Q.F., Xi, T., Shen, F., et al., 2010a. Overexpression of asparaginyl-(asparaginyl)-beta-hydroxyaspartate in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 52, 164–173.

Wang, Q., Su, L., Liu, N., Zhang, L., Xu, W., Fang, H., 2011. Cyclic dependent kinase 1 inhibitors: a review of recent progress.Curr. Med. Chem. 18, 2025–2043.

Wang, S., Wu, X., Chen, Y., Zhang, J., Ding, J., Zhou, Y., He, S., Tan, Y., Qiang, F., Bai, J., et al., 2012. Prognostic and predictive role of JWA and XRC1 expresion in gastric cancer. Clin. Cancer Res. 18, 2987–2996.

Wang, S.M., Ooi, L.L., Hui, K.M., 2007. Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res. 13, 6275–6283.

Wang, T., Hu, H.S., Feng, Y.X., Shi, J., Li, N., Guo, W.X., Xue, J., Xie, D., Liu, S.R., Wu, M.C., et al., 2010b. Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma. Br. J. Cancer 102, 1618–1626.

Wang, X.Q., Lo, C.M., Chen, L., Ngan, E.S., Xu, A., Poon, R.Y., 2017. CDK1-PDK1-PI3K/Akt signaling pathway regulates embryonic and induced pluripotency. Cell Death Differ, 34–48.

West, A.C., Johnstone, R.W., 2014. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 124, 30–39.

Woo, H.G., Lee, J.H., Yoon, J.H., Kim, CY., Lee, H.S., Jiang, J.J., Yi, N.J., Suh, K.S., Lee, KU., Park, E.S., et al., 2010. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 70, 3034–3041.

Woo, H.G., Park, E.S., Cheon, J.H., Kim, L.H., Lee, J.S., Park, B.J., Kim, W., Park, S.C., Chung, Y.J., Kim, B.G., et al., 2008. Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma. Clin. Cancer Res. 14, 2056–2064.

Wu, G., Feng, X., Steim, L., 2010. A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 11, R53.

Xu, H., Balakrishnan, K., Malaterre, J., Beasley, M., Yan, Y., Essers, J., Appeldoorn, E., Tomaszewski, J.M., Vazquez, M., Verschoor, S., et al., 2010. Rad21-cohesin haplosufficiency impedes DNA repair and enhances gastrointestinal radiosensitivity in mice. PLoS One 5, e12112.

Xu, H., Beasley, M., Verschoor, S., Iseltten, A., Handel, M.A., McKay, M.J., 2004. A new role for the mitotic RAD21/SCC1 cohesin in meiotic chromosome cohesion and segregation in the mouse. EMBO Rep. 5, 378–479.

Yang, W., Cho, H., Shin, H.Y., Shin, H., Kang, E.S., Lee, E.J., Kim, J.H., 2016. Accumulation of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC. Phosphoproteomics. Mol. Cell. Proteomics 15, 2448–2461.

Yamashita, T., Foruges, M., Wang, W., Kim, J.W., Ye, Q., Jia, H., Budhu, A., Zanni, E.A., Chen, Y., 2008. EpCAM and alpha-feto-protein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res. 68, 1451–1461.

Yao, W., Cho, H., Shin, H.Y., Chung, J.Y., Kang, E.S., Lee, Ej, Kim, J.H., 2016. Accumulation of cytoplasmic CdK1 is associated with cancer growth and survival rate in epithelial ovarian cancer. Oncotarget 7, 49481–49497.

Ye, Q.H., Qin, L.X., Forgues, M., He, P., Kim, J.W., Peng, A.C., Simon, R., Li, Y., Robles, A.I., Chen, Y., et al., 2003. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9, 416–423.

Yoshikawa, S., Takemasa, I., Nagano, H., Kitakata, N., Noda, T., Wada, H., Kobayashi, S., Marubashi, S., Takeda, Y., Umemiya, K., et al., 2009. Molecular prediction of early recurrence after resection of hepatocellular carcinoma. Eur. J. Cancer 45, 881–889.